Treatment decisions in multiple sclerosis are complex given the large number of disease-
modifying therapies with diverse safety and efficacy profiles. The importance of early …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In
recent years, many disease-modifying therapies (DMT) have been approved for MS …

Extracellular vesicles (EVs) represent a new reality for many physiological and pathological
functions as an alternative mode of intercellular communication. This is due to their capacity …

Multiple sclerosis is an important neurological disease affecting millions of young patients
globally. It is encouraging that more than ten disease-modifying drugs became available for …

Importance As disease-modifying treatment options for multiple sclerosis increase,
comparisons of the options based on real-world evidence may guide clinical decision …

The natural history of multiple sclerosis (MS) is highly heterogeneous. A subgroup of
patients has what might be termed aggressive MS. These patients may have frequent …

Studies comparing the effects of natalizumab and fingolimod in relapsing–remitting multiple
sclerosis (RRMS) are limited. We aimed to compare natalizumab and fingolimod effects on …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system of
autoimmune etiopathogenesis, and is characterized by various neurological symptoms …

Background Fingolimod, natalizumab, and ocrelizumab are commonly used in the second-
line treatment of relapsing-remitting multiple sclerosis (RRMS). However, these have only …

Background Evidence regarding the efficacy or effectiveness of the disease-modifying drugs
(DMDs) in the older multiple sclerosis (MS) population is scarce. This has contributed to a …